Offerings from the United States Department of Defense, National Institutes of Health, American Cancer Society, Stand Up To Cancer, and the Society for Immunotherapy of Cancer fellowships are among the offerings in this curated list that may be of interest to Cancer Center members.
DoD Breast Cancer, Transformative Breast Cancer Consortium Development Award
Sponsor: Department of Defense; Department of the Army (USAMRAA)
Abstract: The FY23 Transformative Breast Cancer Consortium Development Award is intended to provide successful applicants the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research to support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds). This is a development award and is a separate mechanism from the full consortium award. Recipients of the FY23 Transformative Breast Cancer Consortium Development Award are expected to submit an application to compete for the full Transformative Breast Cancer Consortium Award anticipated to be offered in a future fiscal year(s). However, it is not necessary to receive a development award in order to apply for a full consortium award in the future. For FY23, investigators may be named as Consortium Director on an application submitted to either (but not both) of these mechanisms. Detailed information on the FY23 Transformative Breast Cancer Consortium Award is available under a separate program announcement (HT945-23-BCRP-TBCCA).
Application Due Date: April 11, 2023
DoD Lung Cancer Research Program Career Development Award
Sponsor: Department of Defense; Department of the Army (USAMRAA)
Abstract: The FY23 LCRP Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. Research applications only in the area of mesothelioma will not be accepted. This award is intended to support impactful research projects with an emphasis on discovery. Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.
Letter of Intent Due Date: May 2, 2023
Application Due Date: May 23, 2023
Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed)
Sponsor: National Institutes of Health (NIH); Department of Health and Human Services (DHHS)
Abstract: This Funding Opportunity Announcement (FOA) entitled “Innovative Research in Cancer Nanotechnology (IRCN)” encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize mechanistic studies toward fundamental understanding of nanomaterial and/or nanodevice interactions with biological systems. These studies should be performed in context of research concerning the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions.
Application Due Date: May 4, 2023
National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)
Sponsor: National Institutes of Health (NIH); Department of Health and Human Services (DHHS)
Abstract: With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.
Application Due Date: May 7, 2023
DoD Ovarian Cancer Research Program Pilot Award
Sponsor: Department of Defense; Department of the Army (USAMRAA)
Abstract: The OCRP Pilot Award supports the exploration of innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward. The proposed research must demonstrate a clear focus on ovarian cancer (e.g., using tissues, cell lines, datasets, or appropriate animal models), and serve as a catalyst to expand or modify current thinking about and/or approaches in ovarian cancer.
Application Due Date: July 21, 2023
The Role of Health Policy and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services
Sponsor: American Cancer Society (ACS)
Abstract: There is a need for research that evaluates the impact of the many changes now occurring in the healthcare system with a particular focus on cancer prevention, control, and treatment. Efforts focusing on improving access to care may also impact inequities that contribute to health disparities. Public health policy initiatives such as the federal and state marketplaces that have expanded insurance coverage, as well as Medicaid expansion in some states, create natural experiments ripe for evaluation. Research to be funded by this RFA should focus on the changes in national, state, and/or local policy and the response to these changes by healthcare systems, insurers, payers, communities, practices, and patients.
A clear understanding of these changes can help clinicians, health systems, public health and public policy professionals, patient and consumer advocates, and providers to identify and guide needed improvements in cancer prevention and control and health care and health more broadly. Findings from this research may also inform advocacy and policy development by the American Cancer Society Cancer Action Network (ACS CAN) in the context of meaningful health care reform by assessing outcomes related to the structure of the health system on availability, administrative simplicity, adequacy, and affordability of coverage, referred to as the 4 A’s, which make up the Society and Cancer Action Network’s framework for reform.
Application Due Date: April 1, 2023
SU2C Diversity In Early Development Community Engagement Grants
Sponsor: Stand Up To Cancer (SU2C)
Abstract: TSU2C invites applications for the Diversity In Early Development Community Engagement Grants. The grants support grassroots level engagement to increase participation in early development clinical trials among minority and traditionally underrepresented populations. Two-year grants ranging from $50,000 to $100,000 will be awarded to organizations located in the communities where the SU2C Diversity in Early Development Teams are conducting their research: (1) Chicago, Illinois, (2) Dallas, Texas, (3) Los Angeles, California, and (4) Philadelphia, Pennsylvania. In doing so, community engagement grant recipients will support the program’s efforts to increase clinical trial participation in their respective communities. We are particularly interested in community engagement strategies and practices that can be replicated and sustained after the funding period has ended.
Application Due Date: April 7, 2023
Notice of Special Interest (NOSI): Administrative Supplement to Support Health Policy Research in Cancer Prevention and Control
Sponsor: National Cancer Institute (NCI)
Abstract: The purpose of this Notice is to encourage currently funded NCI extramural investigators to apply for administrative supplements to support cancer-related policy research including empirical evaluation of policy or evaluation of policy implementation or dissemination methods.
The goals of these administrative supplements on cancer-related health policy are to: 1) generate new or utilize secondary data that operationalize policies hypothesized to affect cancer control at the geographic, provider, patient, and/or temporal level; 2) examine the effects of existing policies and/or simulate the potential effects of new policies, with an emphasis on understanding health disparities by examining differential impacts on disadvantaged groups; 3) identify effective community-engaged strategies for dissemination or implementation of evidence to inform policymaking.
Application Due Dates: April 22, 2023
Notice of Special Interest (NOSI): Administrative supplements to conduct systematic evidence reviews on the clinical utility of cancer-site specific polygenic risk scores (PRS) for cancer risk assessment
Sponsor: National Cancer Institute (NCI)
Abstract: The purpose of this Notice is to encourage currently funded NCI extramural investigators to apply for administrative supplements to conduct systematic evidence reviews assessing the state of the science on the clinical utility (CU) of cancer-site specific polygenic risk scores (PRS) for cancer risk assessment and inform future trials and research directions for clinical translation and implementation. The goals of this supplement opportunity are to 1) identify the potential for CU of cancer-site specific PRS for cancer risk assessment; 2) describe the state of the science in terms of cancer-site specific PRS development and evaluation; 3) assess the current evidence for efficacy and/or effectiveness of PRS CU and potential benefits and harms of their clinical use (including consideration of available screening and prevention interventions based on risk); and 4) propose criteria and optimal study designs and methods for which PRS are candidates for evaluation of CU through clinical trials.
Application Due Dates: April 22, 2023
NCI Requests Cancer Targets for Monoclonal Antibody Production and Characterization
Sponsor: National Cancer Institute (NCI)
Abstract: In an effort to provide well-characterized monoclonal antibodies to the scientific community, NCI’s Antibody Characterization Program requests cancer-related protein targets for affinity production and distribution. The program from The Office of Cancer Clinical Proteomics Research provides reagents and other critical resources that support protein/peptide measurements and analysis. Requests will be reviewed and considered for merit based on their justification and contribution to existing NCI-funded projects.
Application Due Dates: March 15, 2023
Society for Immunotherapy of Cancer Fellowship Opportunities
Cancer Immunotherapy Clinical Fellowship
Sponsor: MERK
Abstract: This clinical fellowship supports an MD or combined MD/PhD with a vested interest in furthering the research and translation of cancer immunotherapy.
Application Due Dates: March 27, 2023
Postdoctoral Cancer Immunotherapy Translational Fellowship
Sponsor: Bristol Myers Squibb
Abstract: This cancer immunotherapy translational fellowship aims to support an MD, PhD, or combined MD/PhD individual with a vested interest in furthering the research and translation of cancer immunotherapy.
Application Due Dates: March 27, 2023
Immunotherapy in Lung Cancer Clinical Fellowship
Sponsor: AstraZeneca
Abstract: This clinical fellowship supports an MD or combined MD/PhD degree with a vested interest in furthering the research and translation of immunotherapeutic approaches for the treatment of patients with lung cancer.
Application Due Dates: March 27, 2023
Women in Cancer Immunotherapy Fellowship
Sponsor: Genentech
Abstract: This fellowship supports the development of a female immunotherapy expert who has an MD, a PhD or combined MD/PhD with a vested interest in furthering research in cancer immunotherapy. Priority will be given to female applicants who self-identify ethnic minority status according to the NIH’s guidance on underrepresented populations. U.S.-based applicants only.
Application Due Dates: March 27, 202
Adverse Events in Cancer Immunotherapy Clinical Fellowship
Sponsor: Mallinckrodt Pharmaceuticals
Abstract: This fellowship provides support to an individual with an MD (or equivalent) or combined MD/PhD degree with a vested interest in furthering the research and translation of adverse events in cancer immunotherapy.